

INFORMATION DISCLOSURE CITATION PTO-1449			ATTORNEY'S DKT NO. 23522-0813	APPLICATION NO. 09/467,317		
			APPLICANT Randolph J. Noelle	NOV 6 3 2000		
			FILING DATE December 20, 1999	GROUP 1644 - TECH CENTER 1600/2000		
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<i>M</i>	5,474,771	Dec 1995	Lederman	424	133.1	—
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No
	0555880	Aug 1993	Europe			
	0585943	Mar 1994	Europe			
	WO93/08207	Apr 1993	International			
	WO93/09812	May 1993	International			
	WO94/04570	Mar 1994	International			
	0173494	Mar 1986	Europe			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
Markees et al. <i>Transplant Proc.</i> 28:814-815 (1996).						
Gerritse et al. <i>PNAS</i> 93:2499-2504 (1996).						
Tisch et al. <i>PNAS</i> 91:437-438 (1994).						
Sharkey et al. <i>Cancer Res (Suppl)</i> 55:5935s-5945s (1995) p. 5935s. <i>10</i>						
Larsen et al. <i>Transplantation</i> 61:4-9 (1996). <i>1700</i>						
Rossini et al. <i>Cell Transplantation</i> 5:49-52 (1996). <i>RE</i>						
Bhata et al. 9 th <i>Intl. Congress of Immunology</i> San Francisco, CA, USA (1995) p. 317. <i>317</i>						
Pulito et al. <i>J. Immunol.</i> 156:2840-2850 (1996) p. 2840. <i>2840</i>						
Monaco <i>Immunomethods</i> 2:159-170 (1993). <i>ROCK</i>						
Wee et al. <i>Transplantation</i> 58:261-264 (1994). <i>261-264</i>						
Paul Ed. <i>Fundamental Immunology</i> Raven Press (1993) p. 242.						
Marshall et al. <i>J. Clin Immunology</i> 13(3):165-173 (1993).						
Durie, F. et al. "Allogeneic Tolerance Induced by Treatment with an Antibody to the Ligand for CD40: <i>FASEB Journal, Abstracts Part 1</i> , AB. No. 2763, Vol. 8, No. 4, pp. a477 (1994).						
Clark and Ledbetter (1994) "How B and T cells talk to each other" <i>Nature</i> , Vol. 367, pp. 425-428.						
Aruffo et al. "The CD40 ligand, gp39, is defective in activated T cells from patients with X-Linked Hyper-IgM Syndrome" <i>Cell</i> , Vol. 72 (1993) pp. 291-300.						
Korthäuer et al. "Defective expression of T cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM" <i>Nature</i> , Vol. 361 (1993) pp. 539-541.						
<i>M</i> DiSanto et al. "CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM" <i>Nature</i> , Vol. 361 (1993) pp. 541-543.						
EXAMINER <i>GAMMER</i>	DATE CONSIDERED <i>3/23/01</i>					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION		ATTORNEY'S DKT NO. 23522-0813	APPLICATION NO. 09/467,341		
PTO-1449		RECEIVED OCT 31 2000 PATENT & TRADEMARK OFFICE U.S. PATENT DOCUMENTS			
		GROUP 1644			
		NOV 02 2000 TECH CENTER 1600 FEE FWD			
U.S. PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS
					C 1700
					109
FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS
					203
					004
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<i>MC</i>	Allen et al. "CD40 ligand gene defects responsible for X-linked Hyper-IgM Syndrome" <i>Science</i> , Vol. 259 (1993) pp. 990-993.				
	Ranheim et al. "Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal" <i>Journal of Experimental Medicine</i> , Vol. 177 (1993) pp. 925-935.				
	Foy et al. "In Vivo CD40-gp39 Interactions are essential for Thymus-dependent Humoral Immunity. IL Prolonged suppression of the Humoral Immune Response by an antibody to the ligand for CD40, gp39" <i>Journal of Experimental Medicine</i> , Vol. 178 (1993) pp. 1567-1575.				
	Lin et al. "Long-Term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA41g Plus Donor-specific Transfusion" <i>Journal of Experimental Medicine</i> , Vol. 178 (1993) pp. 1801-1806.				
	Harris "Therapeutic antibodies - the coming of age" <i>TIBTECH</i> , Vol. 11 (1993) pp. 42-44.				
	Noelle et al. "CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation" <i>Immunology Today</i> , Vol. 13 (1992) pp. 431-433.				
	Noelle et al. "A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells" <i>Proceedings of the National Academy of Sciences</i> , Vol. 89 (1992) pp. 6550-6554.				
	Hollenbaugh et al. "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity" <i>EMBO Journal</i> , Vol. 11, No. 12 (1992) pp. 4313-4321.				
	Armitage et al. "Molecular and biological characterization of a murine ligand for CD40" <i>Nature</i> , Vol. 357 (1992) pp. 80-82.				
	Lane et al. "Activated human T cells express a ligand for the human B cell-associated CD40 which participates in T-cell-dependent activation of B lymphocytes" <i>European Journal of Immunology</i> , Vol. 22 (1992) pp. 2573-2578.				
<i>ML</i>	Lederman et al. "Identification of a novel surface protein on activated CD4 ⁺ T cells that induces contact-dependent B cell differentiation (Help)" <i>Journal of Experimental Medicine</i> , Vol. 175 (1992) pp. 1091-1101.				
EXAMINER	<i>GAMBEL 3/23/01</i>		DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION			ATTORNEY'S DKT NO. 23522-0813	APPLICATION NO. 09/467,317		
			APPLICANT Randolph J. Noelle			
			FILING DATE December 20, 1999	GROUP 1644		
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
<i>M</i>	Spriggs et al. "Recombinant Human CD40 ligand stimulates B cell proliferation and Immunoglobulin E secretion" <i>Journal of Experimental Medicine</i> , Vol. 176 (1992) pp. 1543-1550.					
	Lederman et al. "Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles" <i>Journal of Immunology</i> , Vol. 149, No. 12 (1992) pp. 3817-3826.					
	Fanslow et al. "Soluble forms of CD40 inhibit biological responses of human B cells" <i>Journal of Immunology</i> , Vol. 149, No. 2 (1992) pp. 655-660.					
	Eynon and Parker "Small B Cells as Antigen-presenting Cells in the Induction of Tolerance to Soluble Protein Antigen" <i>Journal of Experimental Medicine</i> , Vol. 175 (1992) pp. 131-138.					
	Linsley et al. "Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule" <i>Science</i> , Vol. 257 (1992) pp. 792-795.					
	Lenschow et al. "Long-term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA41g" <i>Science</i> , Vol. 257 (1992) pp. 798-790.					
	Turka et al. "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo" <i>Proceedings of the National Academy of Sciences</i> , Vol. 89 (1992) pp. 11102-11105.					
	Waldmann "Immune Receptors: Targets for Therapy of Leukemia/Lymphoma, Autoimmune Diseases and for the Prevention of Allograft Rejection" <i>Annu. Rev. Immunol.</i> , Vol. 10 (1992) pp. 675-704.					
	Noelle and Snow "T helper cells" <i>Current Opinion in Immunology</i> , Vol. 4, pp. 333-337.					
	Yellin et al. "A human CD4-T cell Leukemia subclone with contact-dependent helper function" <i>Journal of Immunology</i> , Vol. 147 (1991) pp. 3389-3395.					
<i>M</i>	Waldmann et al. "Monoclonal antibodies in diagnosis and therapy" <i>Science</i> , Vol. 52 (1991) pp. 1657-1662.					
EXAMINER	<i>GAMBEL 3/23/01</i>			DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION			ATTORNEY'S DKT NO. 23522-0813	APPLICATION NO. 09/467,317		
			APPLICANT Randolph J. Noelle			
			FILING DATE December 20, 1999	GROUP 1644		
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation <input type="checkbox"/> Yes <input type="checkbox"/> No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						RECEIVED TO 1700 MAIL ROOM NOV 1 2001
<i>M</i>	Bartlett et al. "Cognate interactions between helper T cells and B cells" <i>Journal of Immunology</i> , Vol. 45, No. 12 (1990) pp. 3956-3962.					
<i>/</i>	Hodgkin et al. "Separation of events mediating B cell proliferation and Ig production by using T cell membranes and lymphokines" <i>Journal of Immunology</i> , Vol. 145, No. 7 (1990) pp. 2025-2034.					
	Aruffo et al. "CD44 Is the Principal Cell Surface Receptor for Hyaluronate" <i>Cell</i> , Vol. 61 (1990) pp. 1303-1313.					
	Stamenkovic et al. "a B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <i>EMBO Journal</i> , Vol. 8, No. 5 (1989) pp. 1403-1410.					
	Paulie et al. "The human B Lymphocyte and Carcinoma Antigen, CDw40, is a Phosphoprotein involved in growth signal transduction" <i>Journal of Immunology</i> , Vol. 142 (1989) pp. 590-595					
	Sharabi et al. "Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen" <i>Journal of Experimental Medicine</i> , Vol. 169 (1989) pp. 493-502.					
	Dillman "Monoclonal antibodies for treating Cancer" <i>Annals of Internal Medicine</i> , Vol. 111, No. 7 (1989), pp. 592-603.					
	Waldmann "Manipulation of T cell responses with monoclonal antibodies" <i>Annu. Rev. Immunol.</i> , Vol. 7 (1989) pp. 4-7-444.					
	Cobbold et al. "Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance" <i>Nature</i> , Vol. 323 (1986) pp. 164-166.					
<i>M</i>	Franco et al., <i>Eur. J. Immunol.</i> , Vol. 24:4 (Apr. 1994) pp. 940-946.					
	Durie et al., <i>Science</i> , Vol. 261:5126 (1993) pp. 1328-1330					
EXAMINER	<i>GAMBL 3/23/01</i>			DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION			ATTORNEY'S DKT NO. 23522-0813	APPLICATION NO. 09/467,317	
PTO-1449			APPLICANT Randolph J. Noelle		
			FILING DATE December 20, 1999	GROUP 1644	
U.S. PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS
FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS
					Translation Yes No
					RECEIVED
					NOV - 1 2000
					MAIL ROOM
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
MG	Mohan et al., <i>FASEB Journal</i> , Vol. 8 (4-5) (Apr. 24-28, 1994) pp. A967				
	Durie et al., <i>Clinical Immunopathol.</i> , Vol. 73(1) (Oct. 1994) pp. 11-18.				
	Laman et al., <i>Journal of Neuroimmunology</i> , Vol. 54 (1-2) (Oct. 23-27, 1994) pp. 5.				
	Harris et al., <i>Tibtech</i> , Vol. 11 (1993) pp. 42-44.				
	Queen et al., <i>Proc. Natl. Acad. Sci.</i> , Vol. 86 (1989) pp. 10029-10033.				
	Vietta et al., <i>Immunol. Rev.</i> , Vol. 99 (1987) pp. 193-239.				
	Bartlett et al., <i>J. Immunol.</i> , Vol. 143 (1989) pp. 1745-1754.				
	Hodgkin et al., <i>J. Immunol.</i> , Vol. 145 (1990) pp. 2025-2034.				
	Noelle et al., <i>J. Immunol.</i> , Vol. 146 (1991) pp. 1118-1124.				
	Bartlett et al., <i>J. Immunol.</i> , Vol. 145 (1990) pp. 3956-3962.				
	Stamenkovic et al., <i>EMBO J.</i> , Vol. 8 (1989) pp. 1403-1410.				
	Aruffo et al., <i>Cell</i> , Vol. 61 (1990) pp. 1303-1313.				
	<i>Nature</i> , Vol. 256 (1975) pp. 495-497.				
	Kozbar et al., <i>Immunology Today</i> , Vol. 4 (1983) pp. 72.				
	Cole et al. "Monoclonal Antibodies and Cancer Therapy" Alan R. Liss, Inc., (1985) pp. 77-96.				
	Morrison et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 81 (1984) pp. 6851-6855.				
	Kurt-Jones et al., <i>J. Exp. Med.</i> , Vol. 166 (1987) pp. 1774-1787.				
	Defranco et al., <i>J. Exp. Med.</i> , Vol. 155 (1982) pp. 1523.				
	Leo et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84 (1987) pp. 1374-1378.				
	Wilde et al., <i>J. Immunol.</i> , Vol. 131 (1983) pp. 2178-2183.				
	Prieto et al., <i>Eur. J. Immunol.</i> , Vol. 19 (1989) pp. 1551-1557.				
EXAMINER	6/23/01		DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.